Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 61.3% in the second quarter, HoldingsChannel.com reports. The firm owned 3,148 shares of the company’s stock after selling 4,994 shares during the quarter. Headlands Technologies LLC’s holdings in Intellia Therapeutics were worth $70,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after buying an additional 746,263 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 5.5% in the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after purchasing an additional 606,507 shares during the period. Norges Bank acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $16,348,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Intellia Therapeutics in the 4th quarter valued at about $9,086,000. Finally, Pinnacle Associates Ltd. acquired a new stake in Intellia Therapeutics in the 1st quarter worth about $7,035,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NTLA. Royal Bank of Canada decreased their target price on Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. decreased their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Stifel Nicolaus dropped their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Stock Down 2.5 %

Shares of NTLA opened at $21.51 on Tuesday. The company has a market cap of $2.18 billion, a P/E ratio of -4.01 and a beta of 1.77. Intellia Therapeutics, Inc. has a fifty-two week low of $19.21 and a fifty-two week high of $35.88. The firm’s 50 day moving average price is $23.38 and its 200 day moving average price is $24.33.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same quarter in the prior year, the firm posted ($1.40) EPS. The company’s quarterly revenue was down 48.5% on a year-over-year basis. Research analysts forecast that Intellia Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.